Browsing: Ozempic

1 medications like semaglutide, the active ingredient in Ozempic and Wegovy, have become some of the most popular drugs in the world. Its popularity is extending to teenagers and young adults, too, research out this week shows

https://p.dw.com/p/5HVXJ The two companies’ diabetes drugs have also become popular for weight lossImage: Jens Kalaene/dpa/picture alliance

Behind those headlines is a real wave of studies, involving millions of patients. I’m a physician and clinical epidemiologist, and my team and I design and interpret these same kinds of studies that test what widely used drugs actually do

New research suggests that a class of medications originally designed to treat type 2 diabetes and aid weight loss may also help reduce binge eating behaviors in people with obesity

Fermentation-derived peptides are starting to turn up in protein products and early-stage bakery and snack formulations, as manufacturers test whether they can deliver a genuine functional benefit rather than simply riding the GLP-1 wave

Many people taking GLP-1 drugs for weight loss have reported strange side effects, ranging from “Ozempic butt” to “Ozempic face” and “Ozempic breasts.”

The growing popularity of GLP-1 medications such as Ozempic, Wegovy, and Rybelsus has largely been driven by their ability to help people lose weight, improve blood sugar control, and reduce the risk of cardiovascular disease. Now, researchers have uncovered another possible benefit. A new clinical trial suggests that semaglutide, the active ingredient in those medications,…

Some people develop long COVID after a SARS-CoV-2 infection, and people with type 2 diabetes have an especially high risk

Apparently, the new weight-loss drugs reduce your appetite for pretty much everything. What hasn’t been noted is the opportunity this presents for the publishing industry – with a new generation of bestselling cookbooks, sex manuals, wine bibles and restaurant guides

South Africa has escalated its crackdown on copycat weight-loss medicines, ordering the recall of compounded versions of Ozempic and Mounjaro while warning doctors, pharmacists and other healthcare professionals that they could face fines, disciplinary action or even lose their licences for prescribing, dispensing or stocking the products